Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/30/24
End: 08/31/26
Due: 08/31/27
Phase: N/A
Priority: Normal
Start: 06/09/24
End: 10/31/39
Due: 10/31/40
Phase: N/A
Priority: Normal
Start: 10/30/24
End: 03/31/27
Due: 03/31/28
Phase: N/A
Priority: Normal
Start: 07/05/22
End: 02/14/25
Due: 02/14/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of VERVE-102 in Patients with Familial Hypercholesterolemia or Premature Coronary Artery Disease | NCT06164730 | Verve Therapeutics, Inc. | user2@example.com | None | 2024-04-30 | 2026-08-31 | 2027-08-31 | - | - | 2025-07-14 |
| Long-term Follow-up of Participants Dosed with an Investigational Gene Editing Therapy for Cardiovascular Disease | NCT06112327 | Verve Therapeutics, Inc. | user2@example.com | None | 2024-06-09 | 2039-10-31 | 2040-10-31 | - | - | 2025-07-14 |
| Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia | NCT06451770 | Verve Therapeutics, Inc. | user2@example.com | None | 2024-10-30 | 2027-03-31 | 2028-03-31 | - | - | 2025-07-14 |
| A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease | NCT05398029 | Verve Therapeutics, Inc. | user2@example.com | None | 2022-07-05 | 2025-02-14 | 2026-02-14 | - | - | 2025-07-14 |